Biotimize is a Brazilian company focused on the development of bioprocesses for the production of biopharmaceuticals (from mammalian cells, yeast, and bacteria). Transforming lives through biotechnology, making dreams, and treatments come true, Biotimize brings the concept of Biotechnology as a Service (BTaaS) to the market. Through this model, Biotimize offers its partner's specialized consultancy, processes development services, and the production of biopharmaceuticals for pre-clinical studies, based on a robust technical-economic analysis, carried out by a team with more than ten years of experience. Investing heavily in the logic of Decentralized Science (DeSci) and notably reducing the costs of its products, Biotimize speeds up the entry of new technologies into the market, mainly in poor or developing countries. Joining this ecosystem, Biotimize has already received investments to build the first biopharmaceutical CDMO in Brazil for the production of clinical and commercial batches (based on mammalian cells). (website under improvement)